AGENUS INC

Insider buying at Agenus (AGUS) shows strong confidence amid a 45% weekly rally, new Phase 3 ROBBIN trial, and $340 M private placement—an insider‑backed catalyst for investors.

Insider buying at Agenus signals CEO confidence in its EGFR‑focused pipeline—potential upside amid a modestly volatile, undervalued biotech stock.

Insider buying at Agenus signals CEO confidence; explore how Garo H’s purchases amid a low price and vaccine push could spark a rebound for investors.

Insider option buys at Agenus signal executive confidence in its immuno‑oncology pipeline—potential price rally amid dilution risk.

Insightful analysis of Dr. Armen Garo H’s growing insider buying at Agenus Inc., revealing confidence in its immuno‑oncology pipeline and potential upside for long‑term investors.

Wright Timothy’s purchase of 2,448 deferred units shows insider confidence in Agenus’s oncology pipeline—boosting board alignment, hinting at future share dilution, and signaling long‑term upside.

Armen Garo’s steady insider buying signals confidence in Agenus’s immuno‑oncology future, hinting at potential upside amid market volatility.

Insider buying surge at Agenus Inc. shows CEO Armen Garo purchasing 4,829 shares, signaling confidence in the biotech’s immuno‑oncology pipeline and potential upside amid market buzz.

Explore how Agenus insider moves and a $141 M partnership with Zydus signal potential upside amid a volatile stock and low P/E.